Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

Παρόμοια τεκμήρια

• Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation
  ανά: Barrón, Feliciano, κ.ά.
  Έκδοση: (2018)
• Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis
  ανά: Bria, E., κ.ά.
  Έκδοση: (2011)
• Anti-tumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR Exon 20 Insertions
  ανά: Floc’h, Nicolas, κ.ά.
  Έκδοση: (2018)
• Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
  ανά: Attili, Ilaria, κ.ά.
  Έκδοση: (2020)
• Transglutaminase 2 induces intrinsic EGFR-TKI resistance in NSCLC harboring EGFR sensitive mutations
  ανά: Choi, Junyoung, κ.ά.
  Έκδοση: (2019)